Editorial
doi: 10.1200/JCO.2005.92.008.
Epub 2005 Jun 13.
Objective response rate as a surrogate end point: a commentary
- PMID: 15955898
- DOI: 10.1200/JCO.2005.92.008
Item in Clipboard
Editorial
Objective response rate as a surrogate end point: a commentary
J Clin Oncol.
.
No abstract available
Comment on
-
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.J Clin Oncol. 2005 Aug 1;23(22):5117-25. doi: 10.1200/JCO.2005.02.106. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955906
Similar articles
-
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.J Clin Oncol. 2005 Aug 1;23(22):5117-25. doi: 10.1200/JCO.2005.02.106. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955906
-
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.J Clin Oncol. 2005 Sep 1;23(25):6139-48. doi: 10.1200/JCO.2005.08.156. J Clin Oncol. 2005. PMID: 16135480
-
Surrogate end points in clinical research: hazardous to your health.Obstet Gynecol. 2005 May;105(5 Pt 1):1114-8. doi: 10.1097/01.AOG.0000157445.67309.19. Obstet Gynecol. 2005. PMID: 15863552 Review.
-
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.J Clin Oncol. 2008 Apr 20;26(12):1987-92. doi: 10.1200/JCO.2007.10.8407. J Clin Oncol. 2008. PMID: 18421050
-
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.J Clin Oncol. 2007 Oct 10;25(29):4562-8. doi: 10.1200/JCO.2006.08.1935. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876010 Review.
Cited by
-
Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.Eur Arch Otorhinolaryngol. 2016 Apr;273(4):837-44. doi: 10.1007/s00405-014-3472-x. Epub 2015 Jan 9. Eur Arch Otorhinolaryngol. 2016. PMID: 25573834 Review.
-
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.Cancer Sci. 2013 Jun;104(6):718-24. doi: 10.1111/cas.12148. Epub 2013 Apr 15. Cancer Sci. 2013. PMID: 23480146 Free PMC article.
-
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Onco Targets Ther. 2012;5:287-96. doi: 10.2147/OTT.S36683. Epub 2012 Oct 23. Onco Targets Ther. 2012. PMID: 23109809 Free PMC article.
-
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.Int J Cancer. 2012 Jan 1;130(1):190-9. doi: 10.1002/ijc.25978. Epub 2011 Apr 20. Int J Cancer. 2012. PMID: 21312195 Free PMC article.
-
Is Participation in Cancer Phase I Trials Really Therapeutic?J Clin Oncol. 2017 Jan 10;35(2):135-138. doi: 10.1200/JCO.2016.67.9902. Epub 2016 Sep 30. J Clin Oncol. 2017. PMID: 27646944 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
